News
The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...
4h
Vietnam Investment Review on MSNLa Roche-Posay and Experts Sound Alarm Over Harmful Burn Line Trend
Viral doesn’t mean safe — global dermatologists unite to warn about the dangerous skincare “hack” hurting young users.
2h
Regtechtimes on MSN🇨🇭 Trump’s tariff blitz hits the Alps — Novartis and Roche brace for tariff pain as Switzerland–U.S. ties collapse
Switzerland, long admired for its calm diplomacy and strict neutrality, has just been hit by a harsh economic surprise. The ...
After 28 years of working for the same public relations agency, Donovan Roche decided that it was time for a change.
Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...
2d
The Punch on MSNNHIA, Roche FMC unveil cost-sharing initiative for cancer treatment
The National Health Insurance Authority, Roche Pharmaceuticals and the Federal Medical Centre, Abuja, have launched a ...
Converging evidence supports a key pathogenic role of the glymphatic system in the accumulation of pathological aggregates in ...
2h
The Cool Down on MSNSkin care enthusiast calls out popular brand over flawed packaging: 'They just quit working'
"They waste so much product." Skin care enthusiast calls out popular brand over flawed packaging: 'They just quit working' ...
Posay's Effaclar A.Z. Gel-Cream is touted as a skincare unicorn. But is it really as good as everyone says it is?
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration: Basel Monday, August 4, 2025, 11:00 Hrs [ ...
14h
MedPage Today on MSNFewer Ocular Pressure Spikes With Drug Vials vs Popular Prefilled Syringes
Investigators defined an IOP spike as >40 mm Hg or an increase ≥10 mm Hg after injection. The population was older (mean age ...
In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results